文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

骨盆骨髓保护调强放疗降低宫颈癌同步放化疗患者血液学毒性:单中心前瞻性随机对照试验

Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
PubMed 文献 · Radiat Oncol · 2020-07-29

该单中心前瞻性随机对照试验纳入164例Ib2-IIIb期宫颈癌患者,随机分为骨盆骨髓保护调强放疗(PBMS-IMRT)组和对照组,对照组接受每周顺铂同步IMRT及腔内近距离治疗,PBMS组额外接受骨盆骨髓剂量约束。结果显示PBMS组≥2级血液学毒性发生率为50.0%,显著低于对照组的69.5%(P=0.02),≥2级胃肠道毒性两组无显著差异。

要点

  • PBMS-IMRT组≥2级血液学毒性发生率为50.0%,显著低于对照组69.5%(P=0.02)。
  • 骨盆PB V40≥28%与≥2级血液学毒性风险升高相关(OR=2.85,P=0.006)。
  • 腰骶椎LSS V10≥87%和LSS mean≥39 Gy与≥2级血液学毒性风险升高相关。

核心结论

  • 与单纯IMRT相比,PBMS-IMRT降低了宫颈癌同步放化疗患者的血液学毒性发生率。
  • 同时维持LSS V10<87%、LSS mean<39 Gy和PB V40<28%可能降低≥2级血液学毒性风险。

研究设计与样本

  • 单中心前瞻性随机对照试验,2018年3月至2019年3月纳入164例Ib2-IIIb期宫颈癌患者,随机分配至PBMS组或对照组,每组82例进行统计分析。
  • 对照组接受每周顺铂同步IMRT,随后行腔内近距离治疗;PBMS组额外接受骨盆骨髓剂量约束。
  • 主要终点为急性血液学或胃肠道毒性,采用受试者工作特征曲线推导最佳剂量学规划约束。

主要发现

  • PBMS组≥2级血液学毒性发生率为50.0%,显著低于对照组的69.5%(P=0.02)。
  • PB V40≥28%的患者更易发生≥2级血液学毒性(OR=2.85,P=0.006)。
  • 两组≥2级胃肠道毒性发生率无显著差异(P>0.05)。
  • LSS剂量学参数与≥2级血液学毒性的关联强于其他亚部位,LSS V10≥87%和LSS mean≥39 Gy的患者更易发生≥2级血液学毒性(OR=3.13,P=0.001;OR=3.03,P=0.002)。

关键数值与推荐

  • PBMS-IMRT组接受骨盆骨髓剂量约束,对照组未接受该约束。
  • PB V40≥28%与≥2级血液学毒性风险升高相关(OR=2.85,P=0.006)。
  • LSS V10≥87%与≥2级血液学毒性风险升高相关(OR=3.13,P=0.001)。
  • LSS mean≥39 Gy与≥2级血液学毒性风险升高相关(OR=3.03,P=0.002)。
  • 同时维持LSS V10<87%、LSS mean<39 Gy和PB V40<28%可能降低≥2级血液学毒性风险。

临床怎么用

  • 对接受同步放化疗的宫颈癌患者,可考虑采用PBMS-IMRT以降低≥2级血液学毒性发生率。
  • 放疗计划设计时,可参考将LSS V10控制在<87%、LSS mean控制在<39 Gy、PB V40控制在<28%以降低≥2级血液学毒性风险。

局限性

  • 本研究为单中心前瞻性随机对照试验,样本量为164例。
  • 原文未报告随访时间、长期疗效及总生存等终点数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To test the efficacy and feasibility of pelvic bone marrow sparing intensity modulated radiotherapy (PBMS-IMRT) in reducing grade 2 or higher hematological toxicity (HT2+) for patients with cervical cancer treated with concurrent chemoradiotherapy. METHODS AND MATERIALS: A total of 164 patients with Stage Ib2-IIIb cervical cancer were prospectively enrolled from March 2018 to March 2019 at a single center and were randomly allocated into the PBMS group or the control group. The control group received weekly cisplatin concurrently with IMRT, followed by intracavitary brachytherapy. The PBMS group additionally received PBM dose constraint. The dosimetric parameters of the pelvic bone (PB) and the subsites including hip bone (HIP) and lumbosacral spine (LSS) and the corresponding bone marrow were recorded. The endpoint of the trial was acute hematologic or gastrointestinal toxicity. Receiver operating characteristic curves were used to derive optimal dosimetric planning constraints. RESULTS: Eighty-two patients in the PBMS group and 82 in the control group were enrolled for statistical analysis. The incidence of HT2+ in the PBMS group was 50.0%, significantly lower than the 69.5% incidence in the control group (P = 0.02). Patients with PB V40 ≥ 28% were more likely to experience HT2+ (OR = 2.85, P = 0.006), while the incidence of grade 2 or higher gastrointestinal toxicity (GT2+) events did not differ significantly between the two groups (P > 0.05). Dosimetric parameters of LSS showed stronger associations with HT2+ than other subsites. The patients with LSS V10 ≥ 87% and LSS mean ≥ 39 Gy were more likely to experience HT2+ (OR = 3.13, P = 0.001;OR = 3.03, P = 0.002, respectively). CONCLUSION: PBMS-IMRT reduced HT compared with IMRT alone. Efforts to maintain LSS V10 < 87%, LSS mean < 39 Gy and PB V40 < 28% simultaneously may reduce the risk of HT2 +. TRIAL REGISTRATION: The trial was registered with Chinese clinical trial registry ( ChiCTR1800015069 ).

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Huang J, Gu F, Ji T, et al. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial. Radiat Oncol. 2020. PMID: 32727497. doi:10.1186/s13014-020-01606-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。